ArticleTranslational andrology and urology2026
Real-world efficacy and safety of disitamab vedotin (RC48) plus PD-1 inhibitors in advanced urothelial carcinoma: a single-center retrospective study.
Ya-Hui Lv et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.